Details

Genetic profiling of NUDT15 in the Slovenian population
ID Šmid, Alenka (Author), ID Urbančič, Dunja (Author), ID Vrevc Žlajpah, Jaka (Author), ID Stollarova, Natalia (Author), ID Prelog, Tomaž (Author), ID Kavčič, Marko (Author), ID Jazbec, Janez (Author), ID Mlinarič-Raščan, Irena (Author), ID Karas Kuželički, Nataša (Author)

.pdfPDF - Presentation file, Download (2,03 MB)
MD5: 3266E220E49443F9444D4056D4BC6A7C
URLURL - Source URL, Visit https://www.tandfonline.com/doi/full/10.1080/14622416.2024.2409060 This link opens in a new window

Abstract
Determining variant TPMT alleles to predict patient response to thiopurine therapy represents one of the first successful implementations of pharmacogenomics in clinical practice. However, despite the TPMT-adjusted thiopurine dosing, some TPMT wild-type patients still exhibit toxicity at standard doses. Over the past decade, the pharmacogene NUDT15 has emerged as a significant co-modulator of thiopurine therapy. Initially, NUDT15 was considered important predominantly in Asian populations, but recent studies have highlighted its relevance in European populations as well. To evaluate the pharmacogenetic significance of NUDT15 in the Slovenian population, we sequenced extended regions of exon 1 and exon 3 in 109 healthy individuals and 37 patients with acute lymphoblastic leukemia. We identified eight variants, including one with established clinical significance (allele *3) and one extremely rare variant (Chr13 at 48045861; GRCh38, NC_000013.11). The frequencies of most previously described variants in both the general population and in the ALL cohort were consistent with those reported in other European populations, except for rs45465203, which was less frequent in the Slovenian population. None of the variants, except for NUDT15*3, were associated with cumulative thiopurine doses in ALL patients. However, these variants warrant further investigation in larger ALL cohorts.

Language:English
Keywords:6-mercaptopurine, acutelymphoblastic leukemia, dose reduction, minorallele frequency, NUDT15, population genetics, thiopurines
Work type:Article
Typology:1.01 - Original Scientific Article
Organization:FFA - Faculty of Pharmacy
MF - Faculty of Medicine
Publication version:Version of Record
Year:2024
Number of pages:Str. 515-525
Numbering:Vol. 25, no. 12-13
PID:20.500.12556/RUL-165844 This link opens in a new window
UDC:616.155.392+575.17
ISSN on article:1744-8042
DOI:10.1080/14622416.2024.2409060 This link opens in a new window
COBISS.SI-ID:213081347 This link opens in a new window
Publication date in RUL:12.12.2024
Views:631
Downloads:140
Metadata:XML DC-XML DC-RDF
:
Copy citation
Share:Bookmark and Share

Record is a part of a journal

Title:Pharmacogenomics
Shortened title:Pharmacogenomics
Publisher:Future Medicine
ISSN:1744-8042
COBISS.SI-ID:521752601 This link opens in a new window

Licences

License:CC BY-NC-ND 4.0, Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International
Link:http://creativecommons.org/licenses/by-nc-nd/4.0/
Description:The most restrictive Creative Commons license. This only allows people to download and share the work for no commercial gain and for no other purposes.

Secondary language

Language:Slovenian
Keywords:6-merkaptopurin, NUDT15, zmanjšanje odmerka, pogostnost manjšega alela, tiopurini, akutna limfoblastna levkemija, populacijska genetika

Projects

Funder:ARIS - Slovenian Research and Innovation Agency
Project number:P1-0208
Name:Farmacevtska kemija: načrtovanje, sinteza in vrednotenje učinkovin

Funder:ARIS - Slovenian Research and Innovation Agency
Project number:I0-0022
Name:Mreža raziskovalnih infrastrukturnih centrov Univerze v Ljubljani (MRIC UL)

Funder:ARIS - Slovenian Research and Innovation Agency
Project number:I0-E011
Name:Izvajanje mednarodnega infrastrukturnega projekta EATRIS

Similar documents

Similar works from RUL:
Similar works from other Slovenian collections:

Back